Brain and Eye Markers of Facial Expression Recognition and Disorders Associated with Autistic Symptoms
NCT ID: NCT05635812
Last Updated: 2024-10-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
120 participants
OBSERVATIONAL
2023-07-06
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is to investigate how processes such as attention or memory influence emotion recognition, as well as (i) their alteration in the disease, and (ii) their link with the emergence of autistic and/or psychotic symptoms. We also want to study the implementation of compensatory strategies (used to compensate for difficulties in recognizing or perceiving emotions) and the link between the correct use of these strategies and the emergence of autistic and/or psychotic symptoms.
The present project plans to include a total of 120 participants: 30 participants with ASD, 30 patients with a particular genetic deletion 22q11.2 and 60 control participants.
After the inclusion visit, participation in the study will be divided into two half-days in order to perform a neuropsychological assessment, an EEG study and an oculometry study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brain and Oculometric Markers of Emotional Facial Expression Recognition Deficits
NCT05501405
Emotional and Change-related Attention in Autism
NCT02160119
Oxytocin Effect on Attentional Bias Towards Emotional Expression Faces in Individuals With High and Low Autistic Traits: A Functional Magnetic Resonance Imaging (fMRI) Study
NCT02741063
Oculomotor Markers and Attachment in Adolescents
NCT02851810
Rt-fMRI NF Intervention Study in ASD
NCT02440451
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants Autism Spectrum Disorders (ASD)
ASD according to DSM-5 criteria
Neuropsychological assessment
neuropsychological assessment and clinical scales duration: 3 hours
EEG experimentation
duration: 1 hour
Oculometry experimentation
duration: 30 minutes
Participants 22q11.2
Participants with a genetic syndrome diagnosed by FISH or CGH-array
Neuropsychological assessment
neuropsychological assessment and clinical scales duration: 3 hours
EEG experimentation
duration: 1 hour
Oculometry experimentation
duration: 30 minutes
Neurotypical participants
Neurotypical development
Neuropsychological assessment
neuropsychological assessment and clinical scales duration: 3 hours
EEG experimentation
duration: 1 hour
Oculometry experimentation
duration: 30 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neuropsychological assessment
neuropsychological assessment and clinical scales duration: 3 hours
EEG experimentation
duration: 1 hour
Oculometry experimentation
duration: 30 minutes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Person whose mother tongue is French.
* Person aged between 7 and 50 years old.
* Person diagnosed with ASD according to DSM-5 criteria, person with a genetic syndrome diagnosed by FISH or CGH array (22q11 deletion), person with typical development matched in age and gender.
* Psychotropic treatment unchanged for one month and stable symptomatology.
Exclusion Criteria
* Pregnant women.
* Uncorrected visual acuity disorder.
* Use of somatic or psychic medication that may alter brain/psychic functioning (e.g. corticosteroids).
* Neurological disorder of vascular/infectious or neurodegenerative origin.
7 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Dijon Bourogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PINOIT 2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.